Top Markets
#1 Ontology Gas Ontology Gas +26.18%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.02%
#5 ETHGas ETHGas +17.85%
#6 Bitway Bitway +15.81%
#7 Geodnet Geodnet +14.32%
#8 Curve DAO Curve DAO +11.70%
#9 Derive Derive +11.25%
#10 The Black Bull The Black Bull +11.14%
Coin of the day
Ontology Gas Ontology Gas
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Xếp hạng trong cổ phiếu #25406
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Giá cổ phiếu
$2.62
Vốn hóa thị trường
$50.19M
Thay đổi (1 ngày)
-1.47%
Thay đổi (1 năm)
77.21%
Quốc gia
JP
Giao dịch Carna Biosciences, Inc. (4572)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Carna Biosciences, Inc. (4572)
Giá đóng cửa cao nhất: $2.33 vào 2026-08-01

Giá đóng cửa thấp nhất: $9.84 vào 2008-03-01
Lịch sử giá cổ phiếu của Carna Biosciences, Inc. từ 2008 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) -2.66%
2025 11.27%
2024 -56.72%
2023 0.20%
2022 -48.88%
2021 -27.88%
2020 -39.08%
2019 101.34%
2018 -2.61%
2017 -38.05%
2016 -28.59%
2015 261.37%
2014 -16.25%
2013 159.13%
2012 -15.00%
2011 -31.55%
2010 -18.51%
2009 -1.93%
2008 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 35.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.21%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $117.80 -18.86%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 8.65%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 397.46%
US